메뉴 건너뛰기




Volumn 92, Issue 4, 2013, Pages 549-550

Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; DRUG DERIVATIVE;

EID: 84877081295     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1607-y     Document Type: Letter
Times cited : (26)

References (9)
  • 1
    • 0028022137 scopus 로고
    • Leukemia: Management of relapse after allogeneic bone marrow transplantation
    • 8040682 1:STN:280:DyaK2czhsFeqtw%3D%3D
    • Kumar L (1994) Leukemia: management of relapse after allogeneic bone marrow transplantation. J Clin Oncol 12:1710-1717
    • (1994) J Clin Oncol , vol.12 , pp. 1710-1717
    • Kumar, L.1
  • 2
    • 33845216261 scopus 로고    scopus 로고
    • Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine
    • 16620971 10.1016/j.leukres.2006.03.003 1:CAS:528:DC%2BD28Xht12ksL7J
    • Graef T, Kuendgen A, Fenk R, Zohren F, Haas R, Kobbe G (2007) Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine. Leuk Res 31:257-259
    • (2007) Leuk Res , vol.31 , pp. 257-259
    • Graef, T.1    Kuendgen, A.2    Fenk, R.3    Zohren, F.4    Haas, R.5    Kobbe, G.6
  • 3
    • 65649120045 scopus 로고    scopus 로고
    • Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia
    • 19235255 10.1002/cncr.24198 1:CAS:528:DC%2BD1MXlt1ygu7o%3D
    • Jabbour E, Giralt S, Kantarjian H, Garcia-Manero G, Jagasia M, Kebriaei P et al (2009) Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 115(9):1899-1905
    • (2009) Cancer , vol.115 , Issue.9 , pp. 1899-1905
    • Jabbour, E.1    Giralt, S.2    Kantarjian, H.3    Garcia-Manero, G.4    Jagasia, M.5    Kebriaei, P.6
  • 4
    • 78649601394 scopus 로고    scopus 로고
    • Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: A dose and schedule finding study
    • 20672358 10.1002/cncr.25500
    • de Lima M, Giralt S, Thall PF, de Padua Silva L, Jones RB, Komanduri K et al (2010) Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 116(23):5420-5431
    • (2010) Cancer , vol.116 , Issue.23 , pp. 5420-5431
    • De Lima, M.1    Giralt, S.2    Thall, P.F.3    De Padua Silva, L.4    Jones, R.B.5    Komanduri, K.6
  • 5
    • 77952419308 scopus 로고    scopus 로고
    • 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: A retrospective analysis
    • 19820729 10.1038/bmt.2009.266 1:CAS:528:DC%2BC3cXlvVOnu7k%3D
    • Czibere A, Bruns I, Kroger N, Platzbecker U, Lind J, Zohren F et al (2010) 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Bone Marrow Transplant 45(5):872-876
    • (2010) Bone Marrow Transplant , vol.45 , Issue.5 , pp. 872-876
    • Czibere, A.1    Bruns, I.2    Kroger, N.3    Platzbecker, U.4    Lind, J.5    Zohren, F.6
  • 6
    • 84857999119 scopus 로고    scopus 로고
    • Azacytidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: Results of the RELAZA trial
    • 10.1038/leu.2011.234
    • Platzbecker U, Wermke M, Radke J, Oelsclaegel U, Seltmann F, Kiani A et al (2012) Azacytidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 36:381-389
    • (2012) Leukemia , vol.36 , pp. 381-389
    • Platzbecker, U.1    Wermke, M.2    Radke, J.3    Oelsclaegel, U.4    Seltmann, F.5    Kiani, A.6
  • 7
    • 84864063679 scopus 로고    scopus 로고
    • Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia
    • 22689805 10.1200/JCO.2011.38.9429 1:CAS:528:DC%2BC38Xht1ygsr%2FI
    • Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J et al (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30:2670-26778
    • (2012) J Clin Oncol , vol.30 , pp. 2670-26778
    • Kantarjian, H.M.1    Thomas, X.G.2    Dmoszynska, A.3    Wierzbowska, A.4    Mazur, G.5    Mayer, J.6
  • 8
    • 0034940793 scopus 로고    scopus 로고
    • Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: Results of a phase i study
    • 11548839 10.1038/sj.bmt.1703028 1:STN:280:DC%2BD3MvpvVyltg%3D%3D
    • Ravandi F, Kantarjian H, Cohen A, Davis M, O'Brien S, Anderlini P et al (2001) Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant 27:1221-1225
    • (2001) Bone Marrow Transplant , vol.27 , pp. 1221-1225
    • Ravandi, F.1    Kantarjian, H.2    Cohen, A.3    Davis, M.4    O'Brien, S.5    Anderlini, P.6
  • 9
    • 84555206702 scopus 로고    scopus 로고
    • Leukocytosis and circulating blasts in older adults with newly diagnosed acute myeloid leukemia: Are they valuable factors for therapeutic decision-making?
    • 10.1016/j.clml.2011.06.003
    • Thomas X, Chelghoum Y, Cannas G, Elhamri M, Labussière H, Tigaud I et al (2011) Leukocytosis and circulating blasts in older adults with newly diagnosed acute myeloid leukemia: are they valuable factors for therapeutic decision-making? Clin Lymphoma Myeloma Leuk 4:342-9
    • (2011) Clin Lymphoma Myeloma Leuk , vol.4 , pp. 342-349
    • Thomas, X.1    Chelghoum, Y.2    Cannas, G.3    Elhamri, M.4    Labussière, H.5    Tigaud, I.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.